Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625250 | 0.94 | — | — | |
| SCHEMBL1371385 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL515400 | 0.91 | — | — | |
| SCHEMBL10019504 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL515120 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL515806 | 0.88 | — | — | |
| SCHEMBL15354433 | 0.86 | — | — | |
| SCHEMBL15444507 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL21988089 | 0.84 | OPRL1 (0.32) | OPRL1 | |
| Hydrochloric Acid SCHEMBL515512 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674846-A1 | UREA MOTIF CONTAINING COMPOUNDS AS ANTIBACTERIAL DRUGS AGAINST MULTIRESISTANT MYCOBACTERIA | Technische Universität München (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| EP-3894410-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-3894409-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| WO-2020124059-A1 | TRICYCLIC COMPOUNDS AS STING AGONISTS, AND PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| EP-3636642-A1 | INDOLEACETIC ACID DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Institute Of Chinese Materia Medica China Academy of Sciences (CN) | 2020-04-15 | — | — | EP | disclosed |
| WO-2020047082-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | Eternity Bioscience Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| EP-2892880-B1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-9447039-B2 | Indole carboxamide derivatives and uses thereof | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | disclosed |
| EP-2892880-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| WO-2014037900-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | OPRL1 159/4885 |
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | OPRL1 2086/4885 |
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | OPRL1 3529/4885 |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | OPRL1 159/4885 |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | OPRL1 2046/4885 |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | OPRL1 2086/4885 |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | ACE2, ACE, SARS1 | OPRL1 2086/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | OPRL1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.